Menarini Group and Insilico Medicine ink agreement for Novel KAT6 inhibitor for treatment of breast cancer
This agreement includes upfront and milestone payments with a combined potential value of over $500m and sales royalties.
This agreement includes upfront and milestone payments with a combined potential value of over $500m and sales royalties.
Marks remarkable acceleration in innovation using AI technology
Innovent will supply sintilimab for the collaborated clinical trial
If approved, Xolair would be the first medicine to reduce allergic reactions to multiple foods following an accidental exposure
If approved, patritumab deruxtecan would be a first-in-class HER3 directed DXd antibody drug conjugate for these patients
V116 is an investigational, 21-valent pneumococcal conjugate vaccine specifically designed to protect adults
The launch of R3SET Detox Candies positions the brand at the forefront of the wellness journey
Five batches across four programs of Biocon Academy participated in the graduation ceremony
Subscribe To Our Newsletter & Stay Updated